Development
Thermo Fisher Scientific Inc.
TMO
$415.15
$0.610.15%
NYSE
| 12/31/2023 | 09/30/2023 | 07/01/2023 | 04/01/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -4.58% | -1.69% | 1.64% | 6.53% | 14.55% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -4.58% | -1.69% | 1.64% | 6.53% | 14.55% |
| Cost of Revenue | -0.90% | 6.15% | 14.55% | 23.03% | 32.55% |
| Gross Profit | -9.62% | -11.50% | -13.14% | -11.10% | -3.40% |
| SG&A Expenses | -6.44% | -3.93% | 0.78% | 5.58% | 13.80% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -2.59% | 3.12% | 10.18% | 17.27% | 26.07% |
| Operating Income | -13.03% | -19.73% | -26.78% | -26.36% | -17.44% |
| Income Before Tax | -18.58% | -19.68% | -28.43% | -24.69% | -13.29% |
| Income Tax Expenses | -59.60% | -55.80% | -68.96% | -54.93% | -36.61% |
| Earnings from Continuing Operations | -14.44% | -15.93% | -23.14% | -20.75% | -9.94% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 500.00% | 238.46% | 54.55% | 0.00% | -233.33% |
| Net Income | -13.74% | -15.51% | -23.09% | -20.77% | -10.03% |
| EBIT | -13.03% | -19.73% | -26.78% | -26.36% | -17.44% |
| EBITDA | -9.13% | -13.07% | -17.48% | -16.35% | -7.87% |
| EPS Basic | -12.51% | -14.39% | -22.30% | -20.21% | -9.58% |
| Normalized Basic EPS | -11.99% | -19.15% | -28.13% | -28.10% | -18.62% |
| EPS Diluted | -12.24% | -14.31% | -22.23% | -20.10% | -9.43% |
| Normalized Diluted EPS | -11.82% | -18.94% | -27.98% | -27.91% | -18.48% |
| Average Basic Shares Outstanding | -1.40% | -1.34% | -1.08% | -0.76% | -0.51% |
| Average Diluted Shares Outstanding | -1.59% | -1.58% | -1.26% | -1.01% | -0.69% |
| Dividend Per Share | 16.67% | 16.38% | 16.07% | 15.74% | 15.38% |
| Payout Ratio | 0.33% | 0.35% | 0.49% | 0.44% | 0.28% |